Related Experiment Video
Updated: Jan 22, 2026
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
TET1 suppresses hepatocellular carcinoma progression by modulating the PI3K/Akt signaling pathways
Shuaiyong Qi1, Ming Chen2, Zhixian Ding1
1Central Laboratory, Wanbei Coal Electric Group General Hospital, Suzhou, 234011, China.
Abstract:
Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with a poor prognosis, underscoring the urgent need to identify novel therapeutic targets. The epigenetic regulator TET1, a key enzyme involved in active DNA demethylation, has been implicated in various cancers, however, its precise role in HCC remains controversial and poorly defined. This study demonstrates that TET1 is significantly upregulated in HCC tissues, and elevated TET1 expression is associated with advanced tumor stage, shorter overall survival and reduced disease-free survival in patients. Functional assays revealed that TET1 knockdown significantly suppressed HCC cell proliferation and induced apoptosis; it also triggered G1-phase cell cycle arrest. Mechanistically, we found that the oncogenic effects of TET1 are mediated through activation of the PI3K/Akt signaling pathway. In summary, our results establish TET1 as a critical promoter of HCC progression and elucidate its role in regulating the PI3K/Akt pathway. These findings highlight its value as both a prognostic biomarker and a potential therapeutic target in HCC.
Insights
TET1, an epigenetic regulator, is upregulated in hepatocellular carcinoma (HCC), promoting tumor growth and progression. Targeting TET1 may offer a new therapeutic strategy for HCC patients.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Hepatocellular carcinoma (HCC) is an aggressive cancer with poor outcomes, necessitating new therapeutic targets.
- The role of TET1, an epigenetic regulator of DNA demethylation, in HCC is not well understood.
- Existing research presents conflicting data regarding TET1's function in various cancers.
Purpose of the Study:
- To investigate the role of TET1 in the progression of hepatocellular carcinoma.
- To determine the prognostic value of TET1 expression in HCC patients.
- To elucidate the molecular mechanisms underlying TET1's function in HCC.
Main Methods:
- Analysis of TET1 expression in HCC tissues and correlation with clinical data.
- In vitro functional assays including TET1 knockdown.
- Cell cycle analysis and apoptosis assays.
- Investigation of signaling pathways, specifically PI3K/Akt.
Main Results:
- TET1 is significantly upregulated in HCC tissues.
- Elevated TET1 expression correlates with advanced tumor stage and poorer patient survival.
- TET1 knockdown inhibits HCC cell proliferation, induces apoptosis, and causes G1 cell cycle arrest.
- TET1 promotes HCC progression via activation of the PI3K/Akt signaling pathway.
Conclusions:
- TET1 acts as a crucial promoter of HCC progression.
- TET1 expression serves as a valuable prognostic biomarker for HCC.
- TET1 represents a potential therapeutic target for hepatocellular carcinoma.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
03:14Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
02:33Hedgehog Signaling Pathway
01:28Insulin: The Receptor and Signaling Pathways